Quantcast

Latest Tapentadol Stories

2011-08-03 07:00:00

SHELTON, Conn., Aug. 3, 2011 /PRNewswire/ -- Cara Therapeutics, Inc. today announced the dosing of the first patient in a Phase II clinical trial of its peripherally-selective, kappa opioid agonist, CR845, for the treatment of acute post-operative pain. The double-blind, placebo-controlled trial is expected to enroll a minimum of 200 patients at multiple clinical sites in the United States, and will evaluate the efficacy and safety of intravenous CR845 administered both pre- and...

2011-08-02 06:00:00

MOUNTAIN VIEW, Calif., Aug. 2, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that its New Drug Application (NDA) for LEVADEX® orally inhaled migraine drug for the potential acute treatment of migraine in adults has been accepted for filing by the U.S. Food and Drug Administration (FDA), with a goal date of March 26, 2012 under the Prescription Drug User Fee Act (PDUFA). In accordance with the Company's collaboration agreement with Allergan,...

2011-07-19 01:00:00

CAMBRIDGE, England, July 19, 2011 /PRNewswire/ -- Convergence Pharmaceuticals Limited ("Convergence"), the company focused on the development of novel and high value analgesic medicines, today announces that the Phase II proof of concept study with CNV1014802 for treating pain associated with lumbosacral radiculopathy (LSR) has started. LSR is a common neuropathic pain condition caused by compression of the nerve roots in the lumbar region of the spine. Common features...

2011-07-18 03:45:00

SYDNEY and BEDMINSTER, N.J., July 18, 2011 /PRNewswire/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today initiation of the New Drug Application (NDA) approval process for MoxDuo IR with the United States Food and Drug Administration (FDA). This NDA submission sets the stage for the regulatory approval process for MoxDuo IR for the treatment of moderate to severe acute pain, a $2.5 billion segment of the $8 billion spent annually on prescription opioids in the US. MoxDuo...

2011-06-29 07:40:00

More comprehensive statistical analysis shows MoxDuo IR, at equi-analgesic doses to either Morphine or Oxycodone, produced significantly less severe respiratory depression SYDNEY and BEDMINSTER, N.J., June 29, 2011 /PRNewswire/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today the release of additional data on its Phase 3 safety study for MoxDuo IR. Study 022 compared the respiratory effects of MoxDuo IR to equi-analgesic doses of either morphine or oxycodone in...

2011-06-07 08:00:00

SAN FRANCISCO, June 7, 2011 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today positive interim data from an ongoing single-dose Phase 1 clinical trial evaluating NKTR-181, the company's novel mu-opioid analgesic candidate. Interim study results show that the molecule achieved its study objectives with an extended PK profile, slow entry into the CNS, and analgesic response. This interim data also show that the drug candidate exhibits an excellent safety and tolerability...

2011-05-31 20:40:00

SEOUL, South Korea, May 31, 2011 /PRNewswire/ -- CrystalGenomics, Inc. (Seoul, Korea) and CG Pharmaceuticals, Inc. (Emeryville, California), a biopharmaceutical company with 3 clinical stage candidates, has announced that the first patient has been enrolled for a Phase 2b clinical study of CG100649, CrystalGenomics' clinical stage novel NSAID candidate, in patients with knee or hip osteoarthritis (OA). CG100649 is a first-in-class NSAID drug candidate that is a dual inhibitor of COX-2 and...


Word of the Day
tesla
  • The unit of magnetic flux density in the International System of Units, equal to the magnitude of the magnetic field vector necessary to produce a force of one newton on a charge of one coulomb moving perpendicular to the direction of the magnetic field vector with a velocity of one meter per second. It is equivalent to one weber per square meter.
This word is named for Nikola Tesla, the inventor, engineer, and futurist.